Optimi Health finishes GMP MDMA batch for Canadian Phase‑3 trial, Australian export and Israeli study
Optimi Health Corp. announced that it has produced a GMP‑compliant batch of MDMA capsules at its Princeton, British Columbia facility. The batch will support a proposed Phase 3 PTSD trial in Canada, a commercial shipment to Australia, and a clinical trial in Israel. The Canadian trial is planned to start in 2027 and could enroll up to 100 participants. Optimi holds the necessary Australian import permits and has secured approval for the Israeli trial, but the products are not yet authorized by Health Canada.
Why it matters
The completed batch positions Optimi to begin patient enrollment in the Canadian Phase 3 study and to start commercial exports to Australia, which could generate future revenue if the trials succeed. However, the lack of Health Canada market authorization means no sales can occur in Canada until approval is obtained.
Key facts
- 1Optimi Health completed a GMP batch of MDMA capsules at its Princeton, British Columbia facility. investing.com
- 2The batch is intended for three programs: a proposed Canadian Phase 3 PTSD trial, a commercial export to Australia, and an Israeli clinical trial with MAPS Israel. investing.com
- 3The Canadian Phase 3 trial is designed to enroll up to 100 participants and is slated to begin in 2027. investing.com
- 4Optimi has obtained Australian import permits for MDMA, with the first shipment expected before the end of 2026. investing.com
- 5The Israeli trial received approval from the Israeli Ministry of Health. investing.com
- 6None of Optimi’s MDMA products have received market authorization from Health Canada. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.